| Bioactivity | TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC50 of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease[1]. |
| In Vivo | TCS2002 (Compound 9b) (1-3 mg/kg;1-24 hours; GS rats andC57BL/6N mice) exhibits good pharmacokinetic profiles and favor able BBB permeability with AUC0-24h value is 734 ng•h/g and Kp value (ratio of brain and plasma) is 1.6[1]. Animal Model: |
| Name | TCS2002 |
| CAS | 1005201-24-0 |
| Formula | C18H14N2O3S |
| Molar Mass | 338.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Morihisa Saitoh, et al. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability. J Med Chem. 2009 Oct 22;52(20):6270-86. |